Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 20/20 | 0.80 |
| ▸ | ELOC | Q15369 | 10/20 | 0.80 |
| ▸ | ELOB | Q15370 | 10/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20975725 | 1.00 | VHL (0.80) | VHLELOCELOB | |
| SCHEMBL15111829 | 0.89 | VHL (1.00) | VHLELOCELOB | |
| SCHEMBL20330215 | 0.89 | VHL (1.00) | VHLELOCELOB | |
| SCHEMBL20975724 | 0.88 | VHL (0.77) | VHLELOCELOB | |
| SCHEMBL21697292 | 0.83 | VHL (0.76) | VHLELOCELOB | |
| SCHEMBL25769085 | 0.83 | VHL (0.76) | VHLELOCELOB | |
| SCHEMBL24623913 | 0.82 | VHL (0.59) | VHLELOCELOB | |
| SCHEMBL20305791 | 0.82 | VHL (0.59) | VHLELOCELOB | |
| SCHEMBL20305792 | 0.82 | VHL (0.59) | VHLELOCELOB | |
| SCHEMBL15125962 | 0.81 | VHL (0.84) | VHLELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12264157-B2 | Compounds and methods for the enhanced degradation of targeted proteins | ARVINAS OPERATIONS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| EP-4414369-A2 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | Arvinas, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-11512083-B2 | Compounds and methods for the enhanced degradation of targeted proteins | ARVINAS OPERATIONS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20200392131-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | Arvinas, Inc. | 2020-12-17 | — | — | US | disclosed |
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | YALE UNIVERSITY (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730870-B2 | Compounds and methods for the enhanced degradation of targeted proteins | ARVINAS OPERATIONS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3608317-A1 | COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | Yale University (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190127359-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | UNIV YALE (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3270917-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | Arvinas, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016149668-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | Arvinas, Inc. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160272639-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512083-B2 | Compounds and methods for the enhanced degradation of targeted proteins | VHL, MDM2, XIAP | VHL 1/4885ELOC 203/4885ELOB 220/4885 |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, ADRM1, MDM2 | VHL 1/4885ELOC 160/4885ELOB 216/4885 |
| US-20200392131-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | VHL 1/4885ELOC 203/4885ELOB 220/4885 |
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | VHL, MDM2, NEDD4 | VHL 1/4885ELOC 185/4885ELOB 209/4885 |
| US-20140356322-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | VHL, MDM2, STUB1 | VHL 1/4885ELOC 190/4885ELOB 241/4885 |
| US-20190127359-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | VHL 2/4885ELOC 211/4885ELOB 249/4885 |
| US-20160272639-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | VHL 1/4885ELOC 203/4885ELOB 220/4885 |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | VHL 1/4885ELOC 203/4885ELOB 220/4885 |
| US-10730870-B2 | Compounds and methods for the enhanced degradation of targeted proteins | VHL, MDM2, XIAP | VHL 1/4885ELOC 203/4885ELOB 220/4885 |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | VHL 2/4885ELOC 211/4885ELOB 249/4885 |
| US-12264157-B2 | Compounds and methods for the enhanced degradation of targeted proteins | VHL, MDM2, XIAP | VHL 1/4885ELOC 203/4885ELOB 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.